After Prometheus sale, Mark McKenna heads to another autoimmune biotech as chair of Apogee

Kyle LaHucik

Senior Reporter

After Mark McKenna sold a biotech for $10.8 billion, the executive recruiters likely came knocking, trying to poach the CEO who took an immunology and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After Prometheus sale, Mark McKenna heads to another autoimmune biotech as chair of Apogee

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Amgen and AstraZeneca share positive results in chronic rhinosinusitis

Eisai slashes Leqembi sales forecast by almost $100M

Charles River to close ‘15 smaller sites’ as demand for early research declines

FDA records request lands Chinese API manufacturer on blocked import list

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Af­ter Prometheus sale, Mark McKen­na heads to an­oth­er au­toim­mune biotech as chair of Apogee

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Am­gen and As­traZeneca share pos­i­tive re­sults in chron­ic rhi­nos­i­nusi­tis

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

FDA records re­quest lands Chi­nese API man­u­fac­tur­er on blocked im­port list

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

After Prometheus sale, Mark McKenna heads to another autoimmune biotech as chair of Apogee

Amgen and AstraZeneca share positive results in chronic rhinosinusitis

Eisai slashes Leqembi sales forecast by almost $100M

Charles River to close ‘15 smaller sites’ as demand for early research declines

FDA records request lands Chinese API manufacturer on blocked import list

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks